Company Overview of Argolyn Bioscience, Inc.
Argolyn Bioscience, Inc., a biotechnology company, discovers and develops peptide drug candidates to treat psychosis, pain, and other serious diseases and disorders. The company’s products are based on amino acid analog substitution technology. The company's products include ABS201 for schizophrenia and ABS212 for pain. Argolyn Bioscience, Inc. was incorporated in 2002 and is based in Durham, North Carolina. Argolyn Bioscience, Inc. is under liquidation.
2530 Meridian Parkway
Durham, NC 27713
Founded in 2002
Key Executives for Argolyn Bioscience, Inc.
Similar Private Companies By Industry
|MicroVAX, LLC||United States|
|LEAD Therapeutics, Inc.||United States|
|Cell Targeting Inc.||United States|
|Targeted Growth, Inc.||United States|
|American Type Culture Collection Inc||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
To contact Argolyn Bioscience, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.